Astragalus 黃芪
Pharmaceutical nameAstragali Radix
The three axes are assessed independently and are never combined into a single score.
KTKP records the origin species as Astragalus membranaceus Bunge. It has not yet been cross-checked against the Korean Pharmacopoeia, so the identification confidence is not raised to an official code mapping. The same drug appears under 3 records as name variants. The name most used for this taxon in current literature is Astragalus membranaceus. Literature searches for this herb also cover Astragalus mongholicus, Astragalus propinquus — the same taxon appears under several names.
Tradition · what the text describes
탕액편
The sub-section within this volume has not been verified against the original text yet.
The KTKP traditional materia medica record (M0001128) gives the origin species as Astragalus membranaceus Bunge, the part used as 뿌리, and the properties as 감(甘), 온(溫). It lists 비(脾), 폐(肺) as the channels entered. The same record cites the Donguibogam (1613) as the source for its indications.
Properties & channel entry: 감(甘), 온(溫) · 비(脾), 폐(肺)
Source species: Astragalus membranaceus Bunge (뿌리)
Modern · documented evidence
Cancer-related Fatigueevidence for this indication
- The indication was derived automatically from the Condition field of 5 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 2 · RCT 1 · preclinical 1
2 systematic review(s) and 1 RCT(s) were found. Size and consistency are not yet assessed.
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Astragalus membranaceus") OR (TITLE_ABS:"Astragalus mongholicus") OR (TITLE_ABS:"Astragalus propinquus")) AND TITLE_ABS:"Cancer-related Fatigue"- Comment on "Efficacy of Astragalus membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies". (2025 · Letter)
- Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. (2025 · Meta-Analysis; Systematic Review; review-article; Journal Article)
- Astragalus membranaceus (Huang Qi) for cancer-related fatigue: A protocol for systematic review and meta-analysis. (2022 · review-article; Journal Article)
- The anti-cancerous activity of adaptogenic herb Astragalus membranaceus. (2021 · Review; Journal Article)
- Database mining and animal experiment-based validation of the efficacy and mechanism of Radix Astragali (Huangqi) and Rhizoma Atractylodis Macrocephalae (Baizhu) as core drugs of Traditional Chinese medicine in cancer-related fatigue. (2022 · Meta-Analysis; Systematic Review; Journal Article)
- A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. (2012 · Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article)
Clinical trials
- NCT01720563 — TERMINATED · PHASE2
- NCT02740959 — COMPLETED · NA
- NCT01720550 — COMPLETED · PHASE4
- NCT03611712 — COMPLETED · PHASE2
- NCT03314805 — COMPLETED · PHASE2
Diabetic Kidney Diseaseevidence for this indication
- Systematic reviews were found but no RCTs. Check the search query (queryUsed).
- The indication was derived automatically from the Condition field of 5 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 3 · RCT 0 · preclinical 10
3 systematic review(s) and 0 RCT(s) were found. Size and consistency are not yet assessed.
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Astragalus membranaceus") OR (TITLE_ABS:"Astragalus mongholicus") OR (TITLE_ABS:"Astragalus propinquus")) AND TITLE_ABS:"Diabetic Kidney Disease"- Current advances and future perspectives of Astragalus membranaceus active components in regulating diabetic microvascular complications. (2026 · Review; Journal Article)
- Astragalus membranaceus improves blood glucose and renal function in diabetic kidney disease mice via gut microbial metabolite axis. (2026 · Journal Article)
- Astragaloside IV Ameliorates Diabetic Kidney Disease via Inhibiting MAPK Pathway and Alleviating Metabolic Dysregulation. (2026 · Journal Article)
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways. (2026 · review-article; Review; Journal Article)
- Research progress in the treatment of lipid metabolism disorder in patients with diabetic kidney disease by the integrated traditional Chinese and Western medicine. (2025 · review-article; Review; Journal Article)
- Molecular Mechanisms Underlying the Anti-Diabetic Effects of Astragaloside IV: A Focus on Signaling Pathways. (2026 · review-article; Review; Journal Article)
- [Different Astragalus medicinal pairs improve diabetic nephropathy in mice by regulating lipid peroxidation through PTGS2]. (2026 · research-article; Journal Article; English Abstract)
- Astragaloside I from Astragalus Attenuates Diabetic Kidney Disease by Regulating HDAC3/Klotho/TGF-β1 Loop. (2024 · Journal Article)
Clinical trials
- NCT07034807 — NOT_YET_RECRUITING · NA
- NCT07657351 — NOT_YET_RECRUITING · NA
- NCT07032116 — NOT_YET_RECRUITING
- NCT03535935 — UNKNOWN · PHASE2, PHASE3
- NCT06176599 — UNKNOWN · NA
Heart Failureevidence for this indication
- Systematic reviews were found but no RCTs. Check the search query (queryUsed).
- The indication was derived automatically from the Condition field of 3 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 4 · RCT 0 · preclinical 31
4 systematic review(s) and 0 RCT(s) were found. Size and consistency are not yet assessed.
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Astragalus membranaceus") OR (TITLE_ABS:"Astragalus mongholicus") OR (TITLE_ABS:"Astragalus propinquus")) AND TITLE_ABS:"Heart Failure"- Astragaloside IV inhibits MAPK pathway and promotes mitochondrial autophagy in rats with heart failure. (2026 · research-article; Journal Article)
- Astragalus membranaceus injection activates mitophagy and protects mitochondrial function in chronic heart failure via inhibiting AKT/mTOR pathway. (2025 · research-article; Journal Article)
- Qishen paste improves cardiac conduction in heart failure by regulating cardiac resident macrophage Connexin43. (2026 · Journal Article)
- Yiqi Huoxue Lishui-based Optimized New Shengmai Powder ameliorates myocardial injury in rats with post-myocardial infarction heart failure by inhibiting oxidative stress-mediated ferroptosis via the cyclic guanosine monophosphate-protein kinase G-glutathione peroxidase 4 axis. (2026 · Journal Article)
- Adaptive bioactivable nanosystems for synergistic myocardial infarction therapy using traditional pharmaceutics. (2025 · research-article; Journal Article)
- Jaranol: a compound with therapeutic activity against pathological cardiac remodelling via multi-target inhibition of the Snai3/TLR2 and NF-κB signaling pathways. (2025 · research-article; Journal Article)
- Computational Modeling of Network Topology and Molecular Dynamics for the Assessment of Therapeutic Potential of the Astragalus Membranaceus-Salvia Miltiorrhiza Drug Pair in the Treatment of Chronic Kidney and Heart Failure. (2025 · Journal Article)
- Shenqi Oral Liquid regulates reactive oxygen species production by modulating autophagy, thereby regulating mitochondrial dynamics in cardiomyocytes and alleviating chronic heart failure in mice via adenosine 5'-monophosphate-activated protein kinase/mechanistic target of rapamycin axis. (2026 · Journal Article)
Clinical trials
- NCT05583773 — RECRUITING · PHASE4
- NCT04667598 — UNKNOWN · PHASE2
- NCT03027375 — UNKNOWN · PHASE2
Safety
auto-proposed · unreviewed
- This signal was read off the NCCIH text by keyword rules. A curator must read the source and confirm it.
- NCCIH states: · There isn’t enough reliable information to know if applying astragalus to the skin is safe or has potential side effects.
- NCCIH states: · Because astragalus might worsen symptoms of autoimmune diseases, people with autoimmune diseases should avoid using astragalus.
- NCCIH states: Also, astragalus may interact with medications that suppress the immune system.
- NCCIH states: · Little is known about whether it’s safe to use astragalus during pregnancy or while breastfeeding.
- NCCIH states: Some research in animals suggests that during pregnancy, astragalus can be toxic to the fetus.
Adverse-event and toxicity literature
This is not a finding of harm — it lists literature that is retrievable. Read the papers to decide.
- Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review. (2026 · Journal Article)
- Astragaloside IV attenuates cisplatin-induced acute kidney injury by suppressing KAT5-mediated NLRP3 acetylation and inflammasome activation. (2026 · Journal Article)
- Targeting mitochondrial permeability and cytosolic mtDNA release: Astragaloside IV suppresses cGAS-STING signaling pathway to protect against cadmium-induced hepatotoxicity. (2026 · Journal Article)
- Astragaloside IV Alleviates Cisplatin Chemotherapy-Induced Nephrotoxicity via Modulation of Nrf2/HO-1/NF-κB Pathway and Reversal of EMT Process. (2025 · Journal Article)
- SHPro® (mixture of Angelica gigas and Astragalus membranaceus) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial. (2025 · Research Support, Non-U.S. Gov't; research-article; Randomized Controlled Trial; Journal Article)
Interaction literature
This lists literature that is retrievable — it is not a judgement that an interaction exists. Read the papers to decide.
- In vitro investigation of the effect of cycloastragenol (CAG) on the cytochrome P450 enzyme activities. (2026 · Journal Article)
- Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review. (2026 · Journal Article)
- Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders. (2026 · Review; Journal Article)
- Effect of Chinese herbs on CYP3A4 activity and expression in vitro. (2013 · Research Support, Non-U.S. Gov't; Journal Article)
- Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. (2018 · Research Support, Non-U.S. Gov't; review-article; Review; Journal Article)
Sources
- KTKP materia medica (15002148) (fetched 2026-08-27)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- KTKP materia medica (15002148) (fetched 2026-08-27)
- NCCIH Herbs at a Glance (fetched 2026-08-27)